Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO versus LINAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO versus LINAGLIPTIN.
JENTADUETO vs LINAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.
5 mg orally once daily
None Documented
None Documented
Clinical Note
moderateLinagliptin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Delavirdine
"The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Clarithromycin
"The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin."
Clinical Note
moderateLinagliptin + Ranolazine
Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Terminal elimination half-life is approximately 12 hours, allowing once-daily dosing. No accumulation at steady state.
Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Approximately 90% of absorbed dose is excreted unchanged in feces (biliary/fecal route), and about 5% is excreted unchanged in urine. Renal excretion is minimal (<1% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor
"The serum concentration of Ranolazine can be increased when it is combined with Linagliptin."